Barclays assumed coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research note released on Wednesday, December 20th, Marketbeat reports. The brokerage issued an equal weight rating and a $6.00 price objective on the biotechnology company’s stock.
Several other research analysts have also recently issued reports on the company. HC Wainwright reissued a buy rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, November 8th. Royal Bank of Canada assumed coverage on BioCryst Pharmaceuticals in a research note on Thursday, September 14th. They set a sector perform rating and a $6.00 target price for the company. JPMorgan Chase & Co. raised their target price on BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the company a neutral rating in a research note on Wednesday, September 6th. Jefferies Group raised BioCryst Pharmaceuticals from a hold rating to a buy rating and upped their target price for the company from $5.00 to $7.00 in a report on Wednesday, September 6th. Finally, Piper Jaffray Companies reaffirmed an overweight rating and set a $15.00 target price (up from $13.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 5th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. BioCryst Pharmaceuticals presently has an average rating of Hold and an average price target of $8.63.
BioCryst Pharmaceuticals (NASDAQ BCRX) traded down $0.04 during mid-day trading on Wednesday, hitting $5.62. The company had a trading volume of 794,377 shares, compared to its average volume of 1,067,213. The firm has a market cap of $556.97, a price-to-earnings ratio of -8.78 and a beta of 3.05. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.53 and a current ratio of 2.53. BioCryst Pharmaceuticals has a twelve month low of $3.95 and a twelve month high of $9.25.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.18) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.18). BioCryst Pharmaceuticals had a negative return on equity of 123.16% and a negative net margin of 167.58%. The firm had revenue of $8.76 million during the quarter, compared to the consensus estimate of $5.05 million. During the same period in the prior year, the business earned ($0.16) EPS. The firm’s revenue was up 12.9% on a year-over-year basis. equities research analysts forecast that BioCryst Pharmaceuticals will post -0.71 earnings per share for the current fiscal year.
In other BioCryst Pharmaceuticals news, CMO William P. Sheridan sold 64,310 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $4.72, for a total value of $303,543.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 5.80% of the company’s stock.
A number of hedge funds have recently modified their holdings of BCRX. Vanguard Group Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 19.9% during the 2nd quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock valued at $33,404,000 after acquiring an additional 996,052 shares during the last quarter. RA Capital Management LLC increased its holdings in shares of BioCryst Pharmaceuticals by 47.9% during the 2nd quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock valued at $28,702,000 after acquiring an additional 1,672,447 shares during the last quarter. Janus Henderson Group PLC acquired a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at about $23,762,000. State Street Corp increased its holdings in shares of BioCryst Pharmaceuticals by 72.0% during the 2nd quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock valued at $21,736,000 after acquiring an additional 1,636,909 shares during the last quarter. Finally, VHCP Management II LLC increased its holdings in shares of BioCryst Pharmaceuticals by 27.9% during the 3rd quarter. VHCP Management II LLC now owns 3,165,457 shares of the biotechnology company’s stock valued at $16,587,000 after acquiring an additional 690,290 shares during the last quarter. 84.69% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/13/barclays-initiates-coverage-on-biocryst-pharmaceuticals-bcrx.html.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.